Lorbrena (lorlatinib) — United Healthcare
uterine sarcoma
Initial criteria
- Diagnosis of uterine sarcoma
- Disease is advanced OR recurrent/metastatic OR inoperable
- Disease is ALK-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lorbrena therapy
Approval duration
12 months